ES2169995B1 - Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno. - Google Patents

Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.

Info

Publication number
ES2169995B1
ES2169995B1 ES200000999A ES200000999A ES2169995B1 ES 2169995 B1 ES2169995 B1 ES 2169995B1 ES 200000999 A ES200000999 A ES 200000999A ES 200000999 A ES200000999 A ES 200000999A ES 2169995 B1 ES2169995 B1 ES 2169995B1
Authority
ES
Spain
Prior art keywords
lip2a
antigen
protein
preparation
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200000999A
Other languages
English (en)
Other versions
ES2169995A1 (es
Inventor
Bedate Carlos Alonso
Rolania Jose Maria Requena
Alvarez Manuel Soto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Leti SA
CBF Leti SA
Original Assignee
Laboratorios Leti SA
CBF Leti SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200000999A priority Critical patent/ES2169995B1/es
Application filed by Laboratorios Leti SA, CBF Leti SA filed Critical Laboratorios Leti SA
Priority to ES01971447.6T priority patent/ES2546301T3/es
Priority to PCT/ES2001/000147 priority patent/WO2001081388A1/es
Priority to PT1971447T priority patent/PT1279679E/pt
Priority to EP01971447.6A priority patent/EP1279679B1/en
Priority to DK01971447.6T priority patent/DK1279679T3/en
Priority to US10/258,165 priority patent/US20030157125A1/en
Priority to AU95175/01A priority patent/AU9517501A/en
Publication of ES2169995A1 publication Critical patent/ES2169995A1/es
Application granted granted Critical
Publication of ES2169995B1 publication Critical patent/ES2169995B1/es
Priority to US11/282,328 priority patent/US20060127418A1/en
Priority to CY20151100892T priority patent/CY1116774T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Composición a base de la proteína Lip2a y su uso en la preparación de un medicamento para suscitar una respuesta inmune contra un antígeno en individuos inmunizados o en grupos celulares. La composición comprende una proteína llamada Lip2a Leishmania formada por una secuencia de aminoácidos codificada por una secuencia de DNA que comprende los nucleótidos: 1-1 de los Nos. 778 a 1231 de la SEQ. ID NO 1 1-2 o formada por una secuencia de nucleótidos capaces de hibridar con la secuencia descrita en 1-1 bajo condiciones de hibridación moderadamente astringentes y que codificaría por lo tanto una proteína similar a la Lip2a. El método comprende incubar dichas células con dicha proteína Lip2a en presencia o no de un antígeno específico de una enfermedad o infección.
ES200000999A 2000-04-17 2000-04-17 Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno. Expired - Fee Related ES2169995B1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ES200000999A ES2169995B1 (es) 2000-04-17 2000-04-17 Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
AU95175/01A AU9517501A (en) 2000-04-17 2001-04-11 Composition containing leishmania LIP2A
PT1971447T PT1279679E (pt) 2000-04-17 2001-04-11 Composição contendo leishmânia lip2a
EP01971447.6A EP1279679B1 (en) 2000-04-17 2001-04-11 Composition containing leishmania lip2a
DK01971447.6T DK1279679T3 (en) 2000-04-17 2001-04-11 A composition containing Leishmania LiP2a
US10/258,165 US20030157125A1 (en) 2000-04-17 2001-04-11 Composition containing leishmania lip2a
ES01971447.6T ES2546301T3 (es) 2000-04-17 2001-04-11 Composición que contiene Leishmania Lip2a
PCT/ES2001/000147 WO2001081388A1 (es) 2000-04-17 2001-04-11 Composición que contiene leishmania lip2a
US11/282,328 US20060127418A1 (en) 2000-04-17 2005-11-18 Composition containing Leishmania Lip2a
CY20151100892T CY1116774T1 (el) 2000-04-17 2015-10-06 Συνθεση η οποια περιεχει lip2a leishmania

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200000999A ES2169995B1 (es) 2000-04-17 2000-04-17 Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.

Publications (2)

Publication Number Publication Date
ES2169995A1 ES2169995A1 (es) 2002-07-16
ES2169995B1 true ES2169995B1 (es) 2003-12-01

Family

ID=8493222

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200000999A Expired - Fee Related ES2169995B1 (es) 2000-04-17 2000-04-17 Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
ES01971447.6T Expired - Lifetime ES2546301T3 (es) 2000-04-17 2001-04-11 Composición que contiene Leishmania Lip2a

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01971447.6T Expired - Lifetime ES2546301T3 (es) 2000-04-17 2001-04-11 Composición que contiene Leishmania Lip2a

Country Status (8)

Country Link
US (2) US20030157125A1 (es)
EP (1) EP1279679B1 (es)
AU (1) AU9517501A (es)
CY (1) CY1116774T1 (es)
DK (1) DK1279679T3 (es)
ES (2) ES2169995B1 (es)
PT (1) PT1279679E (es)
WO (1) WO2001081388A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2863272B1 (fr) * 2003-11-19 2006-06-09 Inst Rech Developpement Ird Nouveaux moyens pour la prevention des leishmanioses
FR2881752B1 (fr) * 2005-02-10 2009-07-31 Inst Rech Pour Le Dev I R D Et Moyens pour l'obtention de promastigotes de leishmanies avirulents, promastigotes obtenus et leurs applications
RU2521499C2 (ru) * 2008-01-18 2014-06-27 Лабораториос Лети, С.Л. Униперсональ ВАКЦИНА, СОДЕРЖАЩАЯ ЭКСТРАКТ РИБОСОМНОГО БЕЛКА (RPE) И Th1- АКТИВИРУЮЩИЙ АДЪЮВАНТ
WO2010010577A1 (en) 2008-07-25 2010-01-28 Department Of Biotechnology Constructing a dna chimera for vaccine development against leishmaniasis and tuberculosis
MX2012000675A (es) 2009-07-13 2012-06-08 Leti Sl Lab Diagnostico de una parasitosis tal como la leishmaniasis usando un extracto de proteinas ribosomicas (rpe).
US9804158B2 (en) * 2013-07-02 2017-10-31 Institut De Recherche Pour Le Développement Peptides and methods for the detection of Leishmaniasis
US10973897B2 (en) * 2016-04-14 2021-04-13 Peptcell Limited Chagas antigens and antibodies and compositions, methods and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2133236B1 (es) * 1997-06-27 2000-04-16 Leti Lab Gen quimerico formado por las secuencias de dna que codifican los determinantes antigenicos de cuatro proteinas de l. infantum, aplicable para el diagnostico serologico de leishmaniosis canina y proteina obtenida.
US6525186B2 (en) * 1998-12-23 2003-02-25 C.B.F. Leti S.A. Chimeric gene formed of the DNA sequences that encode the antigenic determinants of four proteins of L. infantum, useful of serologic diagnosis of canine leishmaniosis and protein obtained
US6458359B1 (en) * 1998-12-23 2002-10-01 C.B.F. Leti S.A. Chimeric gene formed by the dna sequences that encode the antigenic determinants of four proteins of l. infantum and protein encoded by said gene, and pharmacuetical composition useful for preventing and/or treating leishmaniosis in animals or humans
SI1624063T1 (sl) * 1998-12-23 2009-08-31 Leti Sl Lab Himerni gen, ki kodira antigenske determinante štirih beljakovin iz L. infantuma

Also Published As

Publication number Publication date
ES2546301T3 (es) 2015-09-22
CY1116774T1 (el) 2017-03-15
ES2169995A1 (es) 2002-07-16
US20030157125A1 (en) 2003-08-21
EP1279679A1 (en) 2003-01-29
US20060127418A1 (en) 2006-06-15
WO2001081388A1 (es) 2001-11-01
EP1279679B1 (en) 2015-07-08
DK1279679T3 (en) 2015-08-24
PT1279679E (pt) 2015-12-24
AU9517501A (en) 2001-11-07

Similar Documents

Publication Publication Date Title
RU2339646C2 (ru) Гибридная и тандемная экспрессия белков нейссерий
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
Vanloubbeeck et al. The immunology of Leishmania infection and the implications for vaccine development
Shpynov et al. Detection and identification of spotted fever group rickettsiae in Dermacentor ticks from Russia and central Kazakhstan.
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
ES2129386T1 (es) Vacuna contra influenza.
Han et al. Xylitol inhibits inflammatory cytokine expression induced by lipopolysaccharide from Porphyromonas gingivalis
PL346299A1 (en) Method of dna vaccination
ITFI920052A1 (it) Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
ES2169995B1 (es) Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
EP0796104A4 (en) THE INTRODUCTION OF NUCLEIC ACID MOLECULES INTO MUCUTINE TISSUE
Daly et al. The cell surface ofAeromonas salmonicidadeterminesin vitrosurvival in cultured brook trout (Salvelinus fontinalis) peritoneal macrophages
BR0010711A (pt) Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
JP2008502695A5 (es)
Literák et al. Restriction fragment length polymorphism and virulence of Czech Toxoplasma gondii strains
CN107551264A (zh) L3和/或l5源作为寄生虫病疫苗或诊断的用途
JP2004503217A5 (es)
Sojar et al. Isolation and characterization of fimbriae from a sparsely fimbriated strain of Porphyromonas gingivalis
AR029966A1 (es) Composicion y metodo para suscitar una respuesta inmune contra un antigeno en individuos inmunizados o en grupos celulares
Tuffrey et al. A mouse model of Haemophilus ducreyi infection (chancroid)
FR2863272B1 (fr) Nouveaux moyens pour la prevention des leishmanioses
Wiechmann et al. History of the plague
BR0013574A (pt) Antìgeno vacina de moraxella
Zhao et al. Immunogenicity of a DNA vaccine expressing the Neospora caninum surface protein NcSRS2 in mice

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020716

Kind code of ref document: A1

Effective date: 20020716

PC2A Transfer of patent
FD2A Announcement of lapse in spain

Effective date: 20211117